(VIANEWS) – Amphastar Pharmaceuticals (AMPH), Stellus Capital Investment Corporation (SCM), NICE Ltd (NICE) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Amphastar Pharmaceuticals (AMPH)
34% sales growth and 24.59% return on equity
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and API. It offers Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, a low molecular weight heparin to prevent and treat deep vein thrombosis; Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; Epinephrine injection for the emergency treatment of allergic reactions; lidocaine jelly, an anesthetic product for urological procedures; lidocaine topical solution for various procedures; phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products for emergency use in hospital settings; morphine injection for use with patient controlled analgesia pumps; and lorazepam injection for surgery and medical procedures. In addition, it offers neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; and Isoproterenol hydrochloride injection for mild or transient episodes of heart block. Further, the company distributes recombinant human insulin active pharmaceutical ingredients (API) and porcine insulin API. It serves hospitals, care facilities, alternate care sites, clinics, and doctors' offices. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.
Earnings Per Share
As for profitability, Amphastar Pharmaceuticals has a trailing twelve months EPS of $2.56.
PE Ratio
Amphastar Pharmaceuticals has a trailing twelve months price to earnings ratio of 21.41. Meaning, the purchaser of the share is investing $21.41 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 24.59%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 50.3%, now sitting on 601.31M for the twelve trailing months.
Yearly Top and Bottom Value
Amphastar Pharmaceuticals’s stock is valued at $54.82 at 15:22 EST, way under its 52-week high of $67.66 and way higher than its 52-week low of $27.99.
Moving Average
Amphastar Pharmaceuticals’s value is below its 50-day moving average of $55.96 and higher than its 200-day moving average of $50.43.
2. Stellus Capital Investment Corporation (SCM)
14.1% sales growth and 3.37% return on equity
Stellus Capital Investment Corporation is a business development company specializing in investments in private middle-market companies. It invests through first lien, second lien, unitranche, and mezzanine debt financing, often with a corresponding equity investment. The fund prefers to invest in US and Canada. The fund seeks to invest in companies with an EBITDA between $5 million and $50 million.
Earnings Per Share
As for profitability, Stellus Capital Investment Corporation has a trailing twelve months EPS of $0.48.
PE Ratio
Stellus Capital Investment Corporation has a trailing twelve months price to earnings ratio of 27.48. Meaning, the purchaser of the share is investing $27.48 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 3.37%.
Volume
Today’s last reported volume for Stellus Capital Investment Corporation is 47182 which is 58.88% below its average volume of 114764.
Sales Growth
Stellus Capital Investment Corporation’s sales growth is 17.3% for the present quarter and 14.1% for the next.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is a negative 8% and a negative 2.2%, respectively.
Revenue Growth
Year-on-year quarterly revenue growth grew by 34.9%, now sitting on 101.19M for the twelve trailing months.
3. NICE Ltd (NICE)
12.4% sales growth and 10.65% return on equity
NICE Ltd., together with its subsidiaries, provides cloud platforms for AI-driven digital business solutions worldwide. It offers CXone, a cloud native open platform; Enlighten, an AI engine for CX that discovers automation opportunities for self-service; digital-entry points solutions that enable organizations to address consumers' needs; and journey orchestration solutions that empower organizations to connect and route customers to deal with the customer's request, and connects them using real time AI-based routing. The company also provides smart self service solutions that empower organizations to build intelligent automated conversations based on data; and prepared agent solutions and tools enable contact center agents to guide and alert them in real time; complete performance solutions that help organizations to record structured and unstructured customer interaction and transaction data; and NICE Evidencentral, an digital evidence management platform for public safety emergency communications, law enforcement, and criminal justice helps agencies. In addition, it offers X-Sight, is an open and flexible AI-cloud platform for financial crime and compliance; Xceed, a cloud platform for comprehensive AML and fraud prevention for small and mid-sized organizations; data intelligence solutions that enable organizations to turn raw data into comprehensive actionable intelligence to prevent and detect financial crimes; AI and analytics technologies to detect and prevent financial crimes in real-time; money laundering and fraud prevention solutions that help organizations adhere to capital markets compliance and anti-money laundering compliance regulations; intelligent investigations solutions; and self-service solutions that provide organizations with customization and self-development capabilities. The company was formerly known as NICE-Systems Ltd. and changed its name to NICE Ltd. in June 2016. NICE Ltd. was founded in 1986 and is based in Ra'anana, Israel.
Earnings Per Share
As for profitability, NICE Ltd has a trailing twelve months EPS of $4.94.
PE Ratio
NICE Ltd has a trailing twelve months price to earnings ratio of 42.08. Meaning, the purchaser of the share is investing $42.08 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.65%.
Sales Growth
NICE Ltd’s sales growth is 8.4% for the present quarter and 12.4% for the next.
Volume
Today’s last reported volume for NICE Ltd is 182751 which is 60.79% below its average volume of 466159.
4. Discover Financial Services (DFS)
10.5% sales growth and 25.21% return on equity
Discover Financial Services, through its subsidiaries, provides digital banking products and services, and payment services in the United States. It operates in two segments, Digital Banking and Payment Services. The Digital Banking segment offers Discover-branded credit cards to individuals; private student loans, personal loans, home loans, and other consumer lending; and direct-to-consumer deposit products comprising savings accounts, certificates of deposit, money market accounts, IRA certificates of deposit, IRA savings accounts and checking accounts, and sweep accounts. The Payment Services segment operates the PULSE, an automated teller machine, debit, and electronic funds transfer network; and Diners Club International, a payments network that issues Diners Club branded charge cards and/or provides card acceptance services, as well as offers payment transaction processing and settlement services. The company was incorporated in 1960 and is based in Riverwoods, Illinois.
Earnings Per Share
As for profitability, Discover Financial Services has a trailing twelve months EPS of $11.26.
PE Ratio
Discover Financial Services has a trailing twelve months price to earnings ratio of 8.65. Meaning, the purchaser of the share is investing $8.65 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 25.21%.
Moving Average
Discover Financial Services’s value is under its 50-day moving average of $98.41 and under its 200-day moving average of $99.37.
Yearly Top and Bottom Value
Discover Financial Services’s stock is valued at $97.44 at 15:22 EST, way under its 52-week high of $122.50 and way above its 52-week low of $79.04.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is a negative 32.9% and a negative 5.6%, respectively.
Previous days news about Discover Financial Services(DFS)
- According to Zacks on Thursday, 18 January, "Discover Financial Services price-consensus-eps-surprise-chart | Discover Financial Services Quote"
5. Antero Midstream Partners LP (AM)
7.4% sales growth and 16.23% return on equity
Antero Midstream Corporation owns and operates midstream energy assets. It owns and operates natural gas gathering pipelines, compression stations, processing and fractionation plants, and water handling and treatment assets in the Marcellus Shale and Utica Shale basins. The company was founded in 2013 and is headquartered in Denver, Colorado.
Earnings Per Share
As for profitability, Antero Midstream Partners LP has a trailing twelve months EPS of $0.73.
PE Ratio
Antero Midstream Partners LP has a trailing twelve months price to earnings ratio of 17.14. Meaning, the purchaser of the share is investing $17.14 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 16.23%.
6. PetIQ (PETQ)
5.6% sales growth and 5.68% return on equity
PetIQ, Inc. operates as a pet medication and wellness company in the United States and internationally. It operates in two segments, Products and Services. The company offers Rx pet medications, which include flea and tick control, heartworm preventatives, arthritis, thyroid, diabetes and pain treatments, antibiotics, and other specialty medications; and develops and manufactures its own proprietary value-branded products, as well as distributes third-party branded medications. It also provides OTC medications and supplies primarily within the flea and tick control, and behavior management categories of the health and wellness industry in various forms, such as spot on (topical) treatments, chewables, oral tablets, and collars. In addition, the company offers health and wellness products that include dental treats and nutritional supplements, which comprise hip and joint, vitamins, and skin and coat products. The company provides its products primarily under the PetIQ, PetArmor, VIP Petcare, VetIQ PetCare, VetIQ, Capstar, Advecta, SENTRY, Sergeants, PetLock, Heart Shield Plus, TruProfen, Betsy Farms, PetAction, Minties, Vera, and Delightibles brands. In addition, the company offers a suite of services at community clinics and wellness centers hosted at pet retailers, including diagnostic tests, vaccinations, prescription medications, microchipping, and wellness checks. It operates through veterinarian, retail, and e-commerce channels. The company was founded in 2010 and is headquartered in Eagle, Idaho.
Earnings Per Share
As for profitability, PetIQ has a trailing twelve months EPS of $0.44.
PE Ratio
PetIQ has a trailing twelve months price to earnings ratio of 44.14. Meaning, the purchaser of the share is investing $44.14 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.68%.
Moving Average
PetIQ’s worth is higher than its 50-day moving average of $18.66 and way higher than its 200-day moving average of $16.40.
Earnings Before Interest, Taxes, Depreciation, and Amortization
PetIQ’s EBITDA is 37.93.
Revenue Growth
Year-on-year quarterly revenue growth grew by 32.1%, now sitting on 1.07B for the twelve trailing months.
Volume
Today’s last reported volume for PetIQ is 216889 which is 39.33% below its average volume of 357524.
7. Reinsurance Group of America (RGA)
5.3% sales growth and 19.3% return on equity
Reinsurance Group of America, Incorporated engages in reinsurance business. The company offers individual and group life and health insurance products, such as term life, credit life, universal life, whole life, group life and health, joint and last survivor insurance, critical illness, disability, and longevity products; asset-intensive and financial reinsurance products; and other capital motivated solutions. It also provides reinsurance for mortality, morbidity, lapse, and investment-related risk associated with products; and reinsurance for investment-related risks. In addition, the company develops and markets technology solutions; and provides consulting and outsourcing solutions for the insurance and reinsurance industries. It serves life insurance companies in the United States, Latin America, Canada, Europe, the Middle East, Africa, Australia, and the Asia Pacific. Reinsurance Group of America, Incorporated was founded in 1973 and is headquartered in Chesterfield, Missouri.
Earnings Per Share
As for profitability, Reinsurance Group of America has a trailing twelve months EPS of $16.92.
PE Ratio
Reinsurance Group of America has a trailing twelve months price to earnings ratio of 9.94. Meaning, the purchaser of the share is investing $9.94 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 19.3%.
Moving Average
Reinsurance Group of America’s value is above its 50-day moving average of $159.86 and way higher than its 200-day moving average of $146.43.
Growth Estimates Quarters
The company’s growth estimates for the current quarter is 49.5% and a drop 10.7% for the next.
Yearly Top and Bottom Value
Reinsurance Group of America’s stock is valued at $168.24 at 15:22 EST, below its 52-week high of $170.62 and way above its 52-week low of $120.99.
Revenue Growth
Year-on-year quarterly revenue growth grew by 27.2%, now sitting on 17.95B for the twelve trailing months.
